Rifabutin-induced Hypopyon Uveitis in Patients with Acquired Immunodeficiency Syndrome Infected with Mycobacterium avium Complex  by Wang, Hsin-Hui et al.
J Chin Med Assoc • March 2007 • Vol 70 • No 3136
© 2007 Elsevier. All rights reserved.
Introduction
Mycobacterium avium complex (MAC) infection is 
a common opportunistic infection in patients with
acquired immunodeficiency syndrome (AIDS). Since
the number of AIDS patients are increasing in Taiwan,
we should pay more attention to AIDS-related disor-
ders. The US Public Health Service has recommended
rifabutin as prophylaxis for MAC infection in patients
with advanced AIDS at a dosage of 300 mg/day.1 It is
also frequently used in combination therapy for treat-
ment of MAC infection. Usually, rifabutin is well tol-
erated,2 although several cases of rifabutin-induced
uveitis in human immunodeficiency virus (HIV)-
infected patients have been reported since 1994.3–6
But there has been no case described in Taiwan so far.
We report 2 cases of rifabutin-induced hypopyon
uveitis in patients with HIV and MAC infection, and
review the clinical manifestations of this disease.
Case Reports
Case 1
A 26-year-old man was referred to our uveitis clinic
on August 26, 2003. Anterior uveitis of his left eye
was diagnosed 9 days previously at a local clinic, and
the symptoms were relieved gradually after treatment.
However, blurred vision and photophobia developed
in his right eye thereafter.
On tracing the patient’s history, it was found that
he was a case of AIDS under highly active antiretro-
viral combination therapy (HAART) with combivir
(lamivudine 150 mg and zidovudine 300 mg, twice
daily) and nelfinavir (1,250 mg twice daily). He was
also on sulfamethoxazole–trimethoprim, clindamycin
and fluconazole for other opportunistic infections. In
addition, he had received treatment for MAC infec-
tion with a regimen of clarithromycin (500 mg/day),
ethambutol (800 mg/day) and rifabutin (300 mg/
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day) since June 2003. Ocular history was entirely
normal.
On ophthalmic examination, best corrected visual
acuity (BCVA) was 6/10 oculus dexter (OD) and 6/
6.7 oculus sinister (OS). Slit lamp examination showed
1 mm hypopyon with 4+ aqueous cells in the right eye
(Figure 1) and 2+ aqueous cells in the left eye. Fundus
examination showed blurred view in both eyes.
Rifabutin therapy was stopped immediately and
topical steroid with 1% prednisolone acetate 4 times 
a day and 2% homotropine eyedrops twice a day to
both eyes were started. Hypopyon uveitis completely
resolved after 2 weeks. One month later, visual acuity
had improved to 6/6 in both eyes. No recurrence of
uveitis was noted during 2 years of follow-up.
Case 2
A 33-year-old man visited our clinic with the complaints
of sudden blurred vision and severe pain in his left eye
for 1 day on August 24, 2004.
From his past history, the patient was found to have
HIV infection under treatment with HAART with
kaletra (lopinavir 200 mg and ritonavir 50 mg, 3 tablets
q12h), lamivudine (150 mg, twice daily) and stavudine
(40 mg, twice daily). Also, he had cytomegalovirus
(CMV) retinitis in both eyes (Figure 2) under main-
tenance ganciclovir therapy, in addition to clar-
ithromycin, levofloxacin, pyrazinamide (PZA), rifabutin
(300 mg/day) and sulfamethoxazole–trimethoprim for
MAC infection and simultaneous Pneumocystis carinii
pneumonia.
At the time of presentation, BCVA was 6/12 OD
and 6/60 OS. Slit lamp examination showed silent
anterior chamber in the right eye and hypopyon with
3+ aqueous cells and flare in the left eye. Fundoscopic
examination revealed inactive CMV retinitis in the
right eye and obscuration in the left eye. Prednisolone
acetate 1% every 2 hours and atropine 1% 3 times a day
to the left eye were prescribed. Four days later, similar
symptoms in the right eye were reported. Hypopyon
was noted in the right eye (Figure 3). Topical steroid
and mydriatic were applied to both eyes, and rifabutin
therapy was stopped. Two months later, BCVA returned
to 6/12 OD and 6/8.6 OS with silent anterior cham-
ber. No recurrence of uveitis was noted during a 1-year
follow-up period.
Discussion
Causes of uveitis in patients infected with HIV are fre-
quently associated with opportunistic infections, such as
herpes zoster ophthalmicus, tuberculosis, CMV retini-
tis, toxoplasmosis and possibly secondary to HIV itself.7
Usually, it presents as a posterior segment disease.
Hypopyon iritis is not a characteristic of any of these
opportunistic infectious uveitis syndromes.
Rifabutin is a semi-synthetic spiro-piperidyl-
rifamycin S derivative of rifamycin. It was approved by
the FDA in December 1992 for use in HIV-infected
patients with CD4+ cell counts less than 100/mm3
for MAC prophylaxis. It is also a part of the multidrug
Figure 1. Case 1: slit lamp examination of the right eye shows
1 mm hypopyon with 4+ aqueous cells in the anterior chamber.
A B
Figure 2. Case 2: fundus photographs of both eyes reveal cytomegalovirus retinitis. (A) Right eye; (B) left eye.
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regimen for treatment of disseminated MAC infections.
However, uveitis as a side effect of rifabutin therapy
has been recognized since 1994.3–6 Initially, the majority
of these cases were diagnosed as endophthalmitis and
received invasive work-up.
Shafran et al3 conducted a prospective randomized
study of treatment for disseminated MAC infection.
Fifty-nine patients were on a regimen of rifabutin
(600 mg daily), clarithromycin (1,000 mg twice daily)
and ethambutol 15mg/kg of body weight daily. Uveitis
developed in 23 of these 59 patients and it was treated
with topical corticosteroids and mydriatics, with favor-
able outcomes in all patients. Therefore, the MAC
Study Group of the Canadian HIV Trial Network
recommended a reduction in the dose of rifabutin to
300 mg daily and the discontinuation of rifabutin ther-
apy in patients with uveitis.
The pathogenetic mechanisms of rifabutin-induced
uveitis in MAC-infected patients have not yet been
elucidated. Possible pathogenic mechanisms may be
an immune reaction or direct drug toxicity. Saran et al
assumed that the rifabutin-associated uveitis might be
analogous to the Jarisch–Herxheimer reaction when
penicillin is used in the treatment of systemic syphilis.5
An inflammatory response to dead MAC organisms or
their released toxins is plausible. Direct rifabutin toxic-
ity was advocated by Shafran et al,8 as evidenced by
dose-dependency, cumulative time-dependency, involve-
ment of both eyes in most cases when there was rifabutin
maintenance, and reversibility on drug discontinuation.
In this report, both patients presented with uni-
lateral progressing to bilateral anterior uveitis after
rifabutin therapy for about 2 months. The presenta-
tion and response to medication were similar to those
that have been previously reported. Both of them were
receiving rifabutin 300 mg daily and clarithromycin
therapy for pulmonary MAC infection in addition to
HAART. They were being treated with currently recom-
mended multidrug regimens in recommended doses,
but still developed severe uveitis. The main cause was
drug–drug interactions.
Most authors have commented on the increased
risk of rifabutin-induced uveitis in cases of concomitant
treatment with clarithromycin.4,5,9 Clarithromycin is
a member of the macrolide group of antibiotics, which
inhibits cytochrome P450 (CYP450). Clarithromycin
inhibited rifabutin’s metabolism and doubled the blood
level.10 Simultaneous fluconazole or protease inhibitor
treatment also increased the risk by a similar mecha-
nism.4–6,11 Of the available protease inhibitors, ritonavir
has the highest potency in inhibiting CYP450.11 Thus,
reduced rifabutin dosage of 150 mg daily or 150 mg
2–3 times per week is recommended if there is any co-
administration of rifabutin with the protease inhibitors
used in our cases ritonavir and nelfenavir.12
In case 2, immune recovery uveitis may be sus-
pected due to the CMV retinitis history in this era of
HAART. However, immune recovery uveitis is char-
acterized by significant vitritis, cystoid macular edema,
epiretinal membranes and disc edema, rather than
hypopyon as occurred in our cases. Besides, in a prospec-
tive clinical trial of 14 patients with stable CMV retini-
tis and HIV infection during HAART, 12 (89.7%) of
the 14 patients had immune recovery uveitis. The
median CD4+ cell count at baseline in the study was
more than 300 cells/μL.13 The CD4+ cell count in
case 2 was 112 cells/μL. Therefore, immune recovery
uveitis was less likely.
In summary, rifabutin-associated uveitis is an ac-
ceptable and known risk of rifabutin therapy, especially
co-administration of rifabutin with clarithromycin, flu-
conazole, or some protease inhibitors. It can be treated
with topical corticosteroids and mydriatics, with favor-
able outcomes. The discontinuation of rifabutin therapy
is suggested in patients with recalcitrant uveitis if sys-
temic conditions permit. Early recognition of this entity
can prevent invasive ocular procedures and treatments.
To our knowledge, no such case had previously been
reported in Taiwan. We suggest that doctors who pre-
scribe this drug should pay more attention to the ocu-
lar complication, uveitis, and drug–drug interactions.
Ophthalmologists should put this on the list of differ-
ential diagnoses for uveitis.
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